BS:BIOM3 Biomm S.A

Biomm S.A. develops and licenses biotechnological processes for the production of active pharmaceutical ingredients and other industrial applications in the United States, Europe, and Asia. Its technology enables the production of recombinant human insulin. The company develops processes for the production of insulin and other biotech products, as well as processes for other industrial applications, such as enzymes that are used in the production of biofuels. Its technology is also suitable for the production of therapeutic proteins comprising calcitonin, interferons, and growth hormones. Biomm S.A. was founded in 2001 and is headquartered in Belo Horizonte, Brazil.

4.66 BRL
As of 03/22/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Brazil
Country of incorporation:  Brazil
IPO date:  04/29/2009
Stock exchange:    XBSP
Exchange country:   Brazil
Market cap:   772,048,192 BRL
Current dividend yield:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy